Why it matters: mRNA cancer immunotherapies are a central part of BioNTech’s oncology strategy. The result raises the pressure to demonstrate clinical benefit, although the ongoing trial could still succeed through its second primary endpoint: overall survival.

49 Kenyan Agritech startup Rhea has raised US$100,000 from Obudu Capital to support its expansion into Tanzania. The fun…

China’s biodegradable plastics industry is confronting a familiar industrial dilemma: rising production costs are forcin…

Danish agtech startup PerPlant’s AI crop sensor is now available factory-fitted onto new Valtra tractors through a partn…

Revieve has introduced the Revieve Beauty LLM (large language model) Suite to understand the relationships between people, skin, ingredients, products, routines, behaviors, and brands. 

[Disclosure: AgFunderNews’ parent company AgFunder is an investor in OlsAro.] OlsAro—a Swedish startup developing salt t…

Why it matters: The deal adds another source of potential candidates as recent results from Zealand’s major partnered drugs raise questions about their competitiveness. It continues a diversification strategy already underway before those readouts.

Singapore is becoming a key innovation hub for the personal care industry, with major suppliers expanding their regional R&D and creative capabilities in the city-state. Symrise and Lubrizol are the latest to strengthen their Singapore presence, aiming to speed up customer collaboration and deliver solutions tailored to fast-growing Asian markets. 

Lundbeck starts Phase 2 Parkinson’s trial. Lundbeck has begun Phase 2 testing of Lu AF28996 after an open-label Phase 1b study suggested improved motor control in advanced Parkinson’s disease. Among 34 participants treated for six weeks, daily time with good symptom control and without troublesome involuntary movements increased by 3.6 hours, alongside reduced levodopa use. Most adverse events were mild, with nausea, dizziness and falls the most common. The oral dopamine receptor agonist could help address persistent motor fluctuations, but efficacy requires confirmation. The placebo-controlled DARE2 trial will enroll approximately 150 adults. Go deeper.